Annual Reports

  • 10-K (Feb 6, 2014)
  • 10-K (Feb 7, 2013)
  • 10-K (Feb 9, 2011)
  • 10-K (Feb 10, 2010)
  • 10-K (Feb 27, 2009)
  • 10-K (Feb 26, 2008)

 
Quarterly Reports

 
8-K

 
Other

Sigma-Aldrich 10-K 2006
Form 10-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark one)

x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2005

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission file number 0-8135

SIGMA-ALDRICH CORPORATION

(Exact name of Registrant as specified in its charter)

 

Delaware   43-1050617
(State or other jurisdiction of
incorporation or organization)
  (I.R.S. Employer Identification No.)
3050 Spruce Street, St. Louis, Missouri   63103
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code 314-771-5765

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, $1.00 par value; Common Share Purchase Rights

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  x    No  ¨

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  ¨    No  x

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  x    No  ¨

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer  x   Accelerated filer  ¨   Non-accelerated filer  ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  ¨    No  x

Aggregate market value of the voting stock held by non-affiliates of the registrant:

$3,720,771,317   June 30, 2005
Value   Date of Valuation

Number of shares of the Registrant’s common stock, $1.00 par value, outstanding as of March 3, 2006 was 66,873,062.

 


 

– 1 –


The following documents are incorporated by reference in the Parts of Form 10-K indicated below:

 

Documents Incorporated by Reference

  

Parts of Form 10-K into which Incorporated

Pages 17-44 of the Annual Report to Shareholders for the year ended December 31, 2005

   Parts I, II and IV

Proxy Statement for the 2006 Annual Meeting of Shareholders

   Part III

The Index to Exhibits is located on page F-2 of this report.

This Annual Report on Form 10-K (the Report) may be deemed to include or incorporate forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 that involve risk and uncertainty, including financial, business environment and projections, as well as statements that are preceded by, followed by, or that include the words “believes,” “expects,” “anticipates,” “should” or similar expressions, and other statements contained herein regarding matters that are not historical facts. Additionally, the Report contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including, without limitation, statements regarding the Company’s expectations, goals, beliefs, intentions and the like regarding future sales, earnings, return on equity, share repurchases, capital expenditures, acquisitions and other matters. These statements involve assumptions regarding the Company operations, investments, acquisitions and conditions in the markets the Company serves. Although the Company believes its expectations are based on reasonable assumptions, such statements are subject to risks and uncertainties, including, among others, certain economic, political and technological factors. Actual results could differ materially from those stated or implied in the Report, due to, but not limited to, such factors as (1) changes in pricing and the competitive environment, (2) fluctuations in foreign currency exchange rates, (3) the impact of acquisitions and success in integrating and obtaining projected results from the acquisitions, (4) other changes in the business environment in which the Company operates, (5) changes in research funding, (6) uncertainties surrounding government healthcare reform, (7) government regulations applicable to the business, (8) the impact of fluctuations in interest rates, (9) the effectiveness of the Company’s further implementation of its global software systems, (10) the ability to retain customers, suppliers and employees, (11) the success of research and development activities, (12) changes in worldwide tax rates or tax benefits from domestic and international operations, and (13) the outcome of the matters described in Note 12 — Contingent Liabilities and Commitments-to the Company’s consolidated financial statements on page 36 of the 2005 Annual Report, which is incorporated herein by reference. The Company does not undertake any obligation to update these forward-looking statements.

PART I

 

Item 1. Business

 

(a) General Development of Business

Sigma-Aldrich Corporation (“the Company”) was incorporated under the laws of the State of Delaware in May 1975. Effective July 31, 1975 (“Reorganization”), the Company succeeded, as a reporting company, Sigma International, Ltd., the predecessor of Sigma Chemical Company (“Sigma”), and Aldrich Chemical Company, Inc. (“Aldrich”), both of which had operated continuously for more than 20 years prior to the Reorganization. The Company’s principal executive offices are located at 3050 Spruce Street, St. Louis, Missouri, 63103.

On April 23, 2002, the Company announced its decision to sell substantially all the assets of its Diagnostics business and continue to supply customers under contract while seeking to transfer these commitments to other vendors as it sought to discontinue this business. On April 22, 2003, the Company concluded all activities related to the Diagnostics business. The operations of the Diagnostics business are accounted for as discontinued operations, and accordingly, operating results, including cash flows, are segregated in the consolidated financial statements for all periods presented.

On April 14, 2004, the Company acquired the stock of UFC Limited (Ultrafine), a leading supplier of contract chemistry services for all phases of drug development, with capabilities ranging from fundamental research to current Good Manufacturing Practice (cGMP), including the ability to supply active ingredients for clinical trials.

On June 22, 2004, the Company acquired the stock of Tetrionics, Inc., a supplier of high purity vitamin D analogs and services including synthesis and scale up, analytical chemistry, regulatory support and cGMP of active pharmaceutical ingredients across a broad range of structural classes of molecules with a strong emphasis on high potency and cytotoxic compounds.

 

– 2 –


On February 28, 2005, the Company completed its acquisition of all of the outstanding capital securities of JRH Biosciences Pty Ltd., CSL US Inc. and JRH Biosciences Limited, which collectively comprised the JRH Biosciences division (JRH) of CSL Limited for $366.8 million. JRH is a leading global supplier of cell culture and sera products to the biopharmaceutical industry. JRH’s product lines include sera, cell culture media used in the production of therapeutic proteins, reagent growth factors and biological material containers.

On April 1, 2005, the Company acquired the stock of the Proligo Group (Proligo), a global supplier of key genomics research tools including custom DNA, custom RNA and phosphoramidite raw materials used for DNA and RNA synthesis, from Degussa AG.

 

(b) Financial Information About Segments

The Company operates in one segment. Information concerning sales for the Company’s business units is provided in Note 14 to the Company’s consolidated financial statements on page 38 of the 2005 Annual Report, which is incorporated herein by reference.

 

(c) Narrative Description of Business

The Company develops, manufactures and distributes the broadest range of high quality biochemicals and organic chemicals available in the world. These chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company operates in 35 countries, offers over 100,000 chemical and 30,000 equipment products and sells these products into over 150 countries.

Products

Prior to 2006, the Company consisted of three business units, Scientific Research, Biotechnology and SAFC (Fine Chemicals), which define the Company’s approach to serving customers.

The Scientific Research unit sells biochemicals, organic chemicals, reagents and other products used by customers at universities, government institutions, non-profit organizations, and pharmaceutical, diagnostic and biotechnology companies. These products represented approximately 70% of the Scientific Research unit sales in each of the years 2005, 2004, and 2003. The Scientific Research unit also sells complex and very pure organic and inorganic chemicals and analytical reagents used in high technology research. These products represented the remaining 30% of Scientific Research sales in each of the years 2005, 2004 and 2003.

The Biotechnology unit supplies immunochemical, cell culture, molecular biology, cell signaling and neuroscience biochemicals and kits used in biotechnology, genomic and proteomic research as well as chromatography products used in life science research and high technology applications.

The SAFC (Fine Chemicals) unit is a top 10 supplier of large-scale organic chemicals and biochemicals used in development and production by pharmaceutical, biotechnology, industrial and diagnostic companies.

Effective January 1, 2006, the Company implemented a new customer-centric organizational structure featuring the Research units of Essentials, Specialties and Biotech, along with the acquisition-enhanced Fine Chemicals unit, SAFC.

The Company expects sales growth in 2006 to benefit from its new customer-centric organizational structure. Each of these units have launched new marketing, investment and process improvement initiatives to drive sales growth in 2006, building on the Company’s Internet superiority, expanding in faster growing world economies and making strategic acquisitions.

Status of Products

Due to continuing developments in life science, high technology and other scientific research, there can be no assurance of a continuing market for each of the Company’s products. However, through ongoing reviews of technical literature, along with regular communications with customers, the Company’s goal is to keep abreast of the trends in research techniques. This information, along with the Company’s own research technology, determines the Company’s development of improved and/or additional products.

Sales and Distribution

During 2005, products were sold to over 60,000 accounts representing over 1,000,000 individual customers, including hospitals, universities, pharmaceutical, industrial, diagnostics and biotechnology companies and commercial laboratories as well as non-profit organizations and governmental institutions. Orders in laboratory quantities averaging approximately $400 accounted for 74%, 81% and 82% of the Company’s sales in 2005, 2004 and 2003, respectively. The Company also makes its chemical products available in larger-scale laboratory

 

– 3 –


quantities for use in manufacturing. Sales of these products accounted for 26%, 19% and 18% of sales in 2005, 2004 and 2003, respectively.

Customers and potential customers, wherever located, are encouraged to contact the Company by telephone (“collect” or on “toll-free” WATS lines) or via its homepage on the World Wide Web (sigma-aldrich.com) for technical staff consultation or for placing orders. Information on the website does not constitute a part of this report. Shipments are made at least five days a week from all locations. The Company strives to ship its products to customers on the same day an order is received and carries inventory levels which it believes to be appropriate to maintain this policy.

Production and Purchasing

The Company has chemical production facilities in Madison, Milwaukee and Sheboygan, Wisconsin; St. Louis, Missouri; Lenexa, Kansas; Houston, Texas; Bellefonte and Denver, Pennsylvania; Natick, Massachusetts; Bethany, Connecticut; Urbana, Illinois; Miamisburg, Ohio; Australia; Canada; France; Germany; India; Israel; Japan; Singapore; Switzerland and the United Kingdom. Biochemicals are primarily produced by extraction and purification from yeasts, bacteria and other naturally occurring animal and plant sources. Organic and inorganic chemicals and radiolabeled chemicals are primarily produced by synthesis. Chromatography media and columns are produced using proprietary chemical synthesis and proprietary preparation processes. Similar processes are used for filtration and sample collection processes.

There are approximately 100,000 chemical and 30,000 equipment products listed in the Sigma, Aldrich, Fluka/ Riedel-de Haën and Supelco catalogs. The Company produces approximately 45,000 of the chemical products, which represented approximately 60% of sales in 2005. Products not manufactured by the Company are purchased from many sources either under contract or in the open market.

None of the Company’s 10,000 suppliers accounted for more than 10% of the Company’s chemical or equipment purchases in 2005. The Company has generally been able to obtain adequate supplies of products and materials to meet its needs. No assurance can be given that shortages will not occur in the future.

Whether a product is produced by the Company or purchased from outside suppliers, it is subjected to quality control procedures, including the verification of purity, prior to final packaging. Quality control is performed by a staff of chemists and lab technicians utilizing highly calibrated equipment.

Patents, Trademarks and Licenses

The Company holds approximately 250 issued or pending patents and has approximately 500 licensing agreements worldwide. The Company’s significant trademarks are the brand names: “Sigma-Aldrich”, “Sigma,” “Aldrich,” “Fluka,” “Riedel-de Haën,” “Supelco,” “SAFC,” “SAFC Biosciences,” “Genosys” and “Proligo.” Prior to 2006, the brands were marketed through business units called “Sigma-Aldrich Scientific Research,” “Sigma-Aldrich Biotechnology” and “Sigma-Aldrich Fine Chemicals (SAFC).” Their related registered logos, and the significant trademarks are expected to be maintained indefinitely.

The Company is aware of the desirability for patent and trademark protection for its products. The Company believes other than its brand names, no single patent, license, trademark (or related group of patents, licenses, or trademarks) is material in relation to its business as a whole.

In addition to patents, the Company relies on trade secrets and proprietary know-how. The Company seeks protection of these trade secrets and proprietary know-how, in part, through confidentiality and proprietary information agreements. The Company makes efforts to require its employees, directors, consultants and advisors, outside scientific collaborators and sponsored researchers, other advisors and other individuals and entities to execute confidentiality agreements upon the start of employment, consulting or other contractual relationships with the Company. These agreements provide that all confidential information developed or made known to the individual or entity during the course of the relationship is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees and some other parties, the agreements provide that all inventions conceived by the individual will be the Company’s exclusive property. These agreements may not provide meaningful protection for or adequate remedies to protect the Company’s technology in the event of unauthorized use or disclosure of information. Furthermore, the Company’s trade secrets may otherwise become known to, or be independently developed by, its competitors.

Dependence on a Single Customer or Product

During the year ended December 31, 2005, no single customer or product accounted for more than 3% or 1 %, respectively, of the Company’s net sales.

 

– 4 –


Backlog

The majority of customer orders are shipped from inventory on the day ordered, resulting in limited backlog. Individual items may occasionally be out-of-stock. These items are shipped as soon as they become available. Some orders for larger scale quantities specify a future delivery date, which can create a small backlog; however, at December 31, 2005 and 2004, the backlog of firm orders and orders for future delivery was not significant. The Company anticipates that substantially all of the December 31, 2005 backlog will be shipped during 2006.

Competition

Substantial competition exists in all of the Company’s marketing and production areas. Although no comprehensive statistics are available, the Company believes it is a major supplier of organic chemicals and biochemicals for research and chromatography products for analyzing and separating complex chemical mixtures. While the Company generally offers thousands of chemicals in stock and analyzes many of its products, some of the Company’s products are unusual and have relatively little demand. There are many competitors who offer a limited quantity of chemicals. In addition, several companies compete with the Company by offering thousands of chemicals, although few of them stock or analyze substantially all of the chemicals they offer for sale.

In all product areas, the Company competes primarily on the basis of customer service, product quality and price. The Company’s main marketing vehicles include the website, sigma-aldrich.com plus over 3,000,000 printed catalogs in the marketplace in 2005 for the Sigma, Aldrich, Fluka, Riedel-de Haën and Supelco brands with customers and potential customers throughout the world. These catalogs are supplemented with advertisements in chemical and other scientific journals, through the use of mailing of special product brochures and by personal visits by sales and technical representatives with customers.

Compliance With Regulations

The Company engages principally in the business of selling products which are not foods or food additives, drugs or cosmetics within the meaning of the Federal Food, Drug and Cosmetic Act, as amended (the “FDC Act”). However, a limited number of the Company’s products are subject to labeling, manufacturing and other provisions of the FDC Act. The Company believes it is in compliance in all material respects with the applicable regulations promulgated under the FDC Act.

The Company believes that it is in compliance in all material respects with federal, state and local regulations relating to the manufacture, sale and distribution of its products. The following are brief summaries of some of the federal laws and regulations which may have an impact on the Company’s business. These summaries are only illustrative of the extensive regulatory requirements of the federal, state and local governments and are not intended to provide the specific details of each law or regulation.

The Chemical Safety Information, Site Security and Fuels Regulatory Relief Act of 1999, and the regulations promulgated thereunder, regulate the handling and storage of certain flammable fuels and require an associated risk management program.

The Clean Air Act (CAA), as amended, and the regulations promulgated thereunder, regulate the emission of harmful pollutants to the air outside of the work environment. Federal or state regulatory agencies may require companies to acquire permits, perform monitoring and install control equipment for certain pollutants.

The Clean Water Act (CWA), as amended, and the regulations promulgated thereunder, regulate the discharge of harmful pollutants into the waters of the United States. Federal or state regulatory agencies may require companies to acquire permits, perform monitoring and to treat waste water before discharge to the waters of the United States or a Publicly Owned Treatment Works (POTW).

The Comprehensive Environmental Response, Compensation and Liability Act of 1980 (CERCLA) and the Superfund Amendments and Reauthorization Act of 1986 (SARA), and the regulations promulgated thereunder, require notification of certain chemical spills and notification to state and local emergency response groups of the availability of MSDS’s and the quantities of hazardous materials in the Company’s possession. SARA, and the regulations promulgated thereunder, also stresses the importance of permanent remedies and innovative treatment technologies to clean up hazardous waste sites.

The Emergency Planning & Community Right-To-Know Act of 1986 (EPCRA), as amended and the regulations promulgated thereunder, regulate Material Safety Data Sheets (MSDS), chemical inventories and chemical release reporting. EPCRA also requires coordinated emergency planning with state and local agencies.

The Occupational Safety and Health Act of 1970 (OSHA), including the Hazard Communication Standard (“Right to Know”), and the regulations promulgated thereunder, require the labeling of hazardous substance containers,

 

– 5 –


the supplying of Material Safety Data Sheets (“MSDS”) on hazardous products to customers and hazardous substances to which an employee may be exposed in the workplace, the training of employees in the handling of hazardous substances and the use of the MSDS, along with other health and safety programs.

The Pollution Prevention Act of 1990 (PPA), as amended, and the regulations promulgated thereunder, focus on reducing the amount of pollution through cost-effective changes in production and raw materials use. Pollution prevention also includes other practices that increase efficiency in the use of energy, water, or other natural resources, and protect our resource base through conservation.

The Resource Conservation and Recovery Act of 1976 (RCRA), as amended, and the regulations promulgated thereunder, require certain procedures regarding the treatment, storage and disposal of hazardous waste.

The Toxic Substances Control Act of 1976 (TSCA), and the regulations promulgated thereunder, require reporting, testing and pre-manufacture notification procedures for certain chemicals. Exemptions are provided from some of these requirements with respect to chemicals manufactured in small quantities solely for research and development use.

The Department of Transportation (DOT) has promulgated regulations pursuant to the Hazardous Materials Transportation Act, referred to as the Hazardous Material Regulations (HMR), which set forth the requirements for hazard labeling, classification, packaging of chemicals and shipment modes destined for shipment in interstate commerce.

The United States Department of Agriculture (USDA), Animal and Plant Health Inspection Service (APHIS), Veterinary Services (VS) regulates the importation of animal-derived materials to ensure that exotic animal and poultry diseases are not introduced into the United States. The USDA has issued importation permits to several Company sites.

Approximately 3,400 products, for which sales are immaterial to the total sales of the Company, are subject to control by either the Drug Enforcement Administration (“DEA”) or the Nuclear Regulatory Commission (“NRC”). The DEA and NRC have issued licenses to several Company sites to permit importation, manufacture, research, analysis, distribution and export of certain products. The Company screens customer orders involving products regulated by the NRC and the DEA to verify that a license, if necessary, has been obtained.

Approximately 900 products, for which sales are immaterial to the total sales of the Company, are subject to licensing by the Department of Commerce (“DOC”). The DOC has promulgated the Export Administration Regulations pursuant to the Export Administration Act of 1979, as amended, to regulate the export of certain products to specific destinations by requiring a special export license.

Approximately 60 products, for which sales are immaterial to the total sales of the Company, are regulated by the Centers for Disease Control (CDC). The U.S. Departments of Health and Human Services (HHS) and Agriculture (USDA) published final rules, which implement the provisions of the USA Patriot Act and Public Health Security and Bioterrorism Preparedness and Response Act of 2002, setting forth the requirements for possession, use, and transfer of select agents and toxins. The CDC has issued one site license to the Company to permit the storage and transfer of these materials.

Approximately 850 products, for which sales are immaterial to the total sales of the Company, are sold as flavoring agents regulated by the Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (Bioterroism Act). The Bioterroism Act requires that the US Food and Drug Administration (FDA) receive prior notice of food items imported into the United States and register facilities handling such items. The Company has registered several sites under the Bioterrorism Act to authorize the importation and handling of these items.

Research and Development

Research and development expenses were 3.0%, 3.0% and 3.3% of sales in 2005, 2004 and 2003, respectively. The research and development expenses relate primarily to efforts to add new manufactured products. All manufactured products accounted for approximately 60% of total sales in 2005.

Number of Persons Employed

The Company had 6,849 employees as of December 31, 2005. The total number employed in the United States was 3,658 with the remaining 3,191 employed by the Company’s international subsidiaries. The Company employs over 2,500 people who have degrees in chemistry, biochemistry, engineering or other scientific disciplines, including approximately 340 with Ph.D. degrees.

 

– 6 –


(d) Financial Information About Geographic Areas

Information concerning sales by geographic area and business unit for the years ended December 31, 2005, 2004 and 2003, is located in Note 14 to the Company’s consolidated financial statements on page 38 of the 2005 Annual Report, which is incorporated herein by reference.

In the years ended December 31, 2005, 2004 and 2003, approximately 61%, 62% and 59%, respectively, of the Company’s sales were to customers located outside the United States. These sales were made directly by the Company, through distributors and by subsidiaries located in 34 other countries.

In October 2004, the American Jobs Creation Act of 2004 (AJCA) was signed into law. The AJCA created temporary incentives for U.S. multinationals to repatriate accumulated earnings outside the U.S. Under the AJCA, the Company repatriated $120.5 million of cash and recorded an income tax charge of $4.1 million in the fourth quarter of 2005. The Company may periodically make additional distributions of undistributed earnings of its foreign subsidiaries to its U.S. parent. These distributions will only be made at such time as the repatriation is deemed to be tax efficient.

The Company’s international operations and United States export sales are subject to certain risks such as changes in the legal and regulatory policies of foreign jurisdictions, local political and economic developments, currency fluctuations, exchange controls, changes in tariff restrictions, royalty and tax increases, export and import restrictions and restrictive regulations of foreign governments, among other factors inherent in these operations. The Company is unable to predict the extent to which its business may be affected in the future by these matters. During 2005, approximately 17% of the Company’s United States operations’ chemical and equipment purchases were from international suppliers.

 

(e) Available Information

Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to reports filed pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, are available on our web site at sigma-aldrich.com as soon as reasonably practicable after being filed electronically with or furnished to the SEC. The content on our website does not constitute part of this Report.

 

(f) Chairman and Executive Officers of the Registrant

The Chairman and executive officers of the Registrant are:

 

Name of Executive Officer

   Age   

Positions and Offices Held

Gilles A. Cottier

   47    President, Research Essentials

David R. Harvey

   66    Chairman of the Board

Michael R. Hogan

   52    Chief Administrative Officer,
Chief Financial Officer and Secretary

David W. Julien

   51    President, Research Specialties

James W. Meteer

   55    Vice President, Process Improvement

Karen J. Miller

   48    Controller

Jai P. Nagarkatti

   59    President and Chief Executive Officer

Douglas W. Rau

   49    Vice President, Human Resources

Kirk A. Richter

   59    Treasurer

Steven G. Walton

   38    Vice President, Safety & Quality

Franklin D. Wicks

   52    President, SAFC

Shahed I. Yousaf

   46    President, Research Biotech

There is no family relationship between any of the officers or directors.

Mr. Cottier was named President of the Research Essentials unit of the Company in July 2005. He served as the Vice President of Sales of the Company from 2003 to 2005 and as Vice President International Sales and Operations of the Company from 1999 to 2003.

Dr. Harvey has been Chairman of the Board since January 2001. He served as the Chief Executive Officer for more than five years until December 31, 2005 and as President of the Company for more than five years until August 2004.

 

– 7 –


Mr. Hogan has been Chief Financial Officer and Chief Administrative Officer of the Company for more than five years.

Mr. Julien was named President of the Research Specialties unit of the Company in July 2005. He served as President of the Biotechnology unit of the Company for more than five years until July 2005.

Mr. Meteer has been Vice President Process Improvement of the Company for more than five years.

Ms. Miller has been Controller of the Company for more than five years.

Dr. Nagarkatti was named Chief Executive Officer of the Company in January 2006. He has been President of the Company since August 2004. He served as Chief Operating Officer of the Company from August 2004 until December 31, 2005. Previously he served as President of the Scientific Research and Fine Chemicals units of the Company from December 2002 to August 2004 and November 1999 to December 2002, respectively.

Mr. Rau joined the Company in October 2005 as Vice President Human Resources. Before joining the Company, Mr. Rau was Vice President Human Resources of Kellwood Company, an apparel marketer, from 2002 to 2005. Prior to that, he was Director of Training and Development at Kellwood Company from 1997 to 2002.

Mr. Richter has been Treasurer of the Company for more than five years.

Mr. Walton joined the Company in August 2005 as Vice President Safety and Quality. Before joining the Company, Mr. Walton was Director of Corporate Health and Safety of ArvinMeritor, an auto parts manufacturer, from 2000 to 2005.

Dr. Wicks was named President of the SAFC unit of the Company in December 2002. He had served as President of the Scientific Research unit from November 1999 to December 2002.

Mr. Yousaf was named President of the Research Biotech unit of the Company in July 2005. He served as the Vice President, Corporate R&D and Biotechnology Marketing of the Company from 2000 to July 2005.

The present terms of office of the Directors will expire when the next annual meeting of the Directors is held and their successors are elected.

 

Item 2. Properties

The following table shows the location, land area, building area and function of the properties the Company owns or leases.

 

Country

   Land Area
(Acres)
    Building Area
(Sq. Ft)
(In thousands)
  

Function

United States

   1,625     4,175    admin., production, warehousing, distrib.

Germany

   46     643    admin., production, warehousing, distrib.

Switzerland

   13     413    admin., production, warehousing, distrib.

United Kingdom

   240     401    admin., production, warehousing, distrib.

Israel

   6     131    admin., production, warehousing, distrib.

All Other

   44     646    admin., production, warehousing, distrib.
             

        Total

   1,974     6,409   

Percent Owned

   82 %     

Percent Leased

   18 %     

The Company considers the properties to be well maintained, in sound condition and repair, and adequate for its present needs. The Company expects to continue to expand its production, warehousing and distribution capabilities in selected markets.

The Company used about 55% of its manufacturing capacity and expects to increase the utilization of its plants in the future.

 

Item 3. Legal Proceedings

The information contained in Note 12 — Contingent Liabilities and Commitments on page 36 of the 2005 Annual Report is incorporated herein by reference.

 

– 8 –


Item 4. Submission of Matters to a Vote of Security Holders

No matters were submitted by the Company to the stockholders for a vote during the fourth quarter of 2005.

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Information concerning the market price of the Company’s Common Stock and related shareholder information for the years ended December 31, 2005 and 2004 is located on page 44 of the 2005 Annual Report under the caption “Common Stock Data,” which is incorporated herein by reference.

See Item 12 for information concerning securities authorized for issuance under equity compensation plans.

The following table represents share repurchases for the year ended December 31, 2005 (in millions except per share amounts):

Issuer Purchases of Equity Securities

 

Period

   Total Number
of Shares
Purchased
   Average Price
Paid per
Share
   Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
   Maximum Number of
Shares that May Yet
Be Purchased Under
the Plans or Programs

Total at Dec 31, 2004

         36.0    4.0

Jan 1, 2005 – Jan 31, 2005

   —        —      36.0    4.0

Feb 1, 2005 – Feb 29, 2005

   —        —      36.0    4.0

Mar 1, 2005 – Mar 31, 2005

   —        —      36.0    4.0

Apr 1, 2005 – Apr 30, 2005

   0.1    $ 58.10    36.1    3.9

May 1, 2005 – May 31, 2005

   0.9    $ 59.49    37.0    3.0

Jun 1, 2005 – Jun 30, 2005

   0.4    $ 57.94    37.4    2.6

Jul 1, 2005 – Jul 31, 2005

   —        —      37.4    2.6

Aug 1, 2005 – Aug 31, 2005

   0.4    $ 62.56    37.8    2.2

Sep 1, 2005 – Sep 30, 2005

   0.1    $ 62.43    37.9    2.1

Oct 1, 2005 – Oct 31, 2005

   —        —      37.9    2.1

Nov 1, 2005 – Nov 30, 2005

   0.1    $ 64.48    38.0    2.0

Dec 1, 2005 – Dec 31, 2005

   —        —      38.0    2.0
                     

Total at Dec 31, 2005

   2.0    $ 60.14    38.0    2.0

On November 11, 2003, the Board of Directors authorized an additional 5 million shares to be repurchased, bringing the total repurchase authorization to 40 million shares. The timing of future repurchases and number of shares repurchased, if any, will depend on market conditions and other factors.

Items 6 through 8. Selected Financial Data, Management’s Discussion and Analysis of Financial Condition and Results of Operations, Quantitative and Qualitative Disclosures about Market Risk and Financial Statements and Supplementary Data

The information required by Items 6 through 8 is incorporated herein by reference to pages 17–44 of the 2005 Annual Report. See Index to Financial Statements on page F-1 of this report. Those pages of the Company’s 2005 Annual Report listed in the Index or referred to in Items 1 through 4 are incorporated herein by reference.

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

None

 

– 9 –


Item 9A. Controls and Procedures

Controls and Procedures

The Company’s Chief Executive Officer and Chief Financial Officer performed an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)), as of December 31, 2005, and determined that such controls and procedures are effective as of that date to provide reasonable assurance that the information required to be disclosed by the Company in the reports it files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. They have also determined in their evaluation that there was no significant change in the Company’s internal controls over financial reporting during the quarter ended December 31, 2005 that has materially affected or is reasonably likely to materially affect the Company’s internal control over financial reporting.

Management’s Report on Internal Control over Financial Reporting and Auditor Attestation Report

The information contained in Management’s Report on Internal Control over Financial Reporting and Report of Independent Registered Public Accounting Firm on pages 42 and 43 of the 2005 Annual Report is incorporated herein by reference.

PART III

 

Item 10. Directors and Executive Officers of the Registrant

Information under the captions “Nominees for Board of Directors” and “Section 16(a) Beneficial Ownership Reporting Compliance” of the 2006 Proxy Statement, which will be filed within 120 days after December 31, 2005, is incorporated herein by reference.

Audit Committee Financial Expert

Information under the caption “Audit Committee” of the 2006 Proxy Statement, which will be filed within 120 days after December 31, 2005, is incorporated herein by reference.

Code of Ethics

The Company has adopted a Code of Ethics applicable to the principal executive officer, principal financial officer and principal accounting officer of the Company. A copy of the Code of Ethics is available on our website at sigma-aldrich.com or may be obtained without charge by writing to the Secretary, Sigma-Aldrich Corporation, P.O. Box 14508, St. Louis, Missouri 63178. The content on our website does not constitute part of this Report.

 

Item 11. Executive Compensation

Information under the captions “Director Compensation and Transactions” and “Information Concerning Executive Compensation” of the 2006 Proxy Statement, which will be filed within 120 days after December 31, 2005, is incorporated herein by reference.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Information under the captions “Security Ownership of Directors, Executive Officers and Principal Beneficial Owners”, “Information Concerning Executive Compensation” and “Equity Compensation Plan Information” of the 2006 Proxy Statement, which will be filed within 120 days after December 31, 2005, is incorporated herein by reference.

 

Item 13. Certain Relationships and Related Transactions

Information, if any, under the captions “Director Compensation and Transactions” and “Principal Beneficial Owners and Transactions” of the 2006 Proxy Statement, which will be filed within 120 days after December 31, 2005, is incorporated herein by reference.

 

Item 14. Principal Accountant Fees and Services

Information under the caption “Audit Firm Fee Summary” of the 2006 Proxy Statement, which will be filed within 120 days after December 31, 2005, is incorporated herein by reference.

 

– 10 –


PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

(a) Documents Filed as Part of this Report

 

  1. Financial Statements

See Index to Financial Statements on page F-1 of this report. Those pages of the Company’s 2005 Annual Report listed in such Index are hereby incorporated by reference.

 

  2. Financial Statement Schedules.

All schedules are omitted as they are not applicable, not required or the information is included in the consolidated financial statements or related notes to the consolidated financial statements.

 

  3. The Company agrees to furnish to the Securities and Exchange Commission, upon request, copies of any long-term debt instruments that authorize an amount of securities constituting 10% or less of the total assets of the Company and its subsidiaries on a consolidated basis.

 

  4. Exhibits

See Index to Exhibits on page F-2 of this report.

 

– 11 –


SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SIGMA-ALDRICH CORPORATION

(Registrant)

 

By   /s/ Karen J. Miller      

March 13, 2006

 

Karen J. Miller, Controller

     

Date

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

 

By   /s/ Jai P. Nagarkatti      

March 13, 2006

 

Jai P. Nagarkatti, President and Chief

Executive Officer (Principal Executive Officer)

     
By   /s/ Karen J. Miller      

March 13, 2006

 

Karen J. Miller, Controller

     

Date

By   /s/ Michael R. Hogan      

March 13, 2006

  Michael R. Hogan, Chief Administrative Officer, Chief Financial Officer and Secretary (Principal Financial Officer)      

Date

By   /s/ David R. Harvey      

March 13, 2006

  David R. Harvey, Chairman of the Board      

Date

By   /s/ Nina V. Fedoroff      

March 13, 2006

  Nina V. Fedoroff, Director      

Date

By   /s/ W. Lee McCollum      

March 13, 2006

  W. Lee McCollum, Director      

Date

By   /s/ Avi M. Nash      

March 13, 2006

  Avi M. Nash, Director      

Date

By   /s/ William C. O’Neil, Jr.      

March 13, 2006

  William C. O’Neil, Jr., Director      

Date

By   /s/ J. Pedro Reinhard      

March 13, 2006

  J. Pedro Reinhard, Director      

Date

By   /s/ Timothy R.G. Sear      

March 13, 2006

  Timothy R.G. Sear, Director      

Date

By   /s/ D. Dean Spatz      

March 13, 2006

  D. Dean Spatz, Director      

Date

By   /s/ Barrett A. Toan      

March 13, 2006

  Barrett A. Toan, Director      

Date

 

– 12 –


SIGMA-ALDRICH CORPORATION AND SUBSIDIARIES

INDEX TO FINANCIAL STATEMENTS AND RELATED INFORMATION

 

    

Page Number

Reference

Annual Report

to Shareholders

Management’s discussion and analysis

   17–25

Market risk disclosure

   24

FINANCIAL STATEMENTS:

  

Consolidated Balance Sheets
December 31, 2005 and 2004

   27

Consolidated statements for the years ended
December 31, 2005, 2004 and 2003

  

Income

   26

Stockholders’ Equity

   28

Cash Flows

   29

Notes to consolidated financial statements

   30–41

Management’s report on internal control over financial reporting

   42

Reports of independent registered public accounting firm

   42–43
Selected financial data, including Common Stock Data and related stockholder information, Annual Financial Data for the five years ended December 31, 2005 and Quarterly Financial Data for the quarterly periods in 2005 and 2004    44

 

F-1


INDEX TO EXHIBITS

These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K:

 

Exhibits     
  2.1       Purchase and Sale Agreement, dated as of January 18, 2005, by and among CSL Limited, CSL International Pty Ltd., and CSL UK Holdings Limited. — Incorporated by reference to Exhibit 2.1 of Form 8-K filed March 1, 2005, Commission File Number 0-8135.
  3 (a)    Certificate of Incorporation and Amendments — Incorporated by reference to Exhibit 3(a) of Form 10-Q filed for the quarter ended June 30, 2004, Commission File Number 0-8135.
    (b)    By-Laws, as amended — Incorporated by reference to Exhibit 3(b) of Form 10-Q for the quarter ended September 30, 2003, Commission File number 0-8135.
  4          Instruments Defining the Rights of Shareholders, Including Indentures:
     (a)    Certificate of Incorporation and Amendments See Exhibit 3(a) above.
     (b)    By-Laws, as amended September 30, 2003 See Exhibit 3(b) above.
     (c)    Rights Agreement, dated as of August 8, 2000 between Sigma-Aldrich Corporation and Computershare Investor Services, LLC, as Rights Agent, which includes the form of Right Certificate as Exhibit A and the Summary of Common Stock Purchase Rights as Exhibit B. — Incorporated by reference to Exhibit 1 of Form 8-A12(g) filed on August 10, 2000, Commission File number 0-8135.
     (d)    The Company agrees to furnish to the Securities and Exchange Commission upon request pursuant to Item 601(b)(4)(iii)of Regulation S-K copies of any instruments defining the rights of holders of long-term debt of the Company and its consolidated subsidiaries.
10          Material Contracts:
     (a)    Share Option Plan of 1987* — Incorporated by reference to Exhibit 10(d) of Form 10-K filed for the year ended December 31, 1992, Commission File Number 0-8135.
     (b)    First Amendment to Share Option Plan of 1987* — Incorporated by reference to Exhibit 10(e) of Form 10-K filed for the year ended December 31, 1992, Commission File Number 0-8135.
     (c)    Second Amendment to Share Option Plan of 1987* — Incorporated by reference to Exhibit 10(f) of Form 10-K filed for the year ended December 31, 1994, Commission File Number 0-8135.
     (d)    Third Amendment to Share Option Plan of 1987* — Incorporated by reference to Exhibit 10(e) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.
     (e)    Fourth Amendment to Share Option Plan of 1987* — Incorporated by reference to Exhibit 10(f) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.
     (f)    Employment Agreement with Chairman of the Board David R. Harvey effective January 1, 2006* — Incorporated by reference to Exhibit 10.1 of Form 8-K filed January 19 ,2006, Commission File Number 0-8135.
     (g)    Share Option Plan of 1995* — Incorporated by reference to Appendix A of the Company’s Definitive Proxy statement filed March 30, 1995, Commission File Number 0-8135.
     (h)    First Amendment to Share Option Plan of 1995* — Incorporated by reference to Exhibit 10(i) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.
     (i)    Second Amendment to Share Option Plan of 1995* — Incorporated by reference to Exhibit 10(j) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.
     (j)    Third Amendment to Share Option Plan of 1995* — Incorporated by reference to Exhibit 10(k) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.
     (k)    Fourth Amendment to Share Option Plan of 1995* — Incorporated by reference to Exhibit 10(l) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.
     (l)    Fifth Amendment to Share Option Plan of 1995* — Incorporated by reference to Exhibit 10(m) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.
     (m)    Directors’ Nonqualified Share Option Plan of 1998* — Incorporated by reference to Exhibit A of the Company’s Definitive Proxy statement filed March 27, 1998, Commission File Number 0-8135.
     (n)    First Amendment to Directors’ Nonqualified Share Option Plan of 1998* — Incorporated by reference to Exhibit 10(o) of Form 10-K filed for the year ended December 31, 2000, Commission File Number 0-8135.

 

F-2


     (o)    Share Option Plan of 2000* — Incorporated by reference to Appendix A of the Company’s Definitive Proxy statement filed March 30, 2000, Commission File Number 0-8135.
     (p)    Form of Employment Agreement (Similar Employment Agreements also exist with Gilles A. Cottier, Michael R. Hogan, David W. Julien, James W. Meteer, Karen J. Miller, Douglas W. Rau, Kirk A. Richter, Steven G. Walton, Franklin D. Wicks and Shahed I. Yousaf)* — See Exhibit 10(p).
     (q)    2003 Long-Term Incentive Plan* — Incorporated by reference to Appendix A of the Company’s Definitive Proxy statement filed March 29, 2003, Commission File Number 0-8135.
     (r)    Cash Bonus Plan* — Incorporated by reference to Appendix B of the Company’s Definitive Proxy statement filed March 29, 2003, Commission File Number 0-8135.
     (s)    Restricted Stock Agreement Under the 2003 Long-Term Incentive Plan* — Incorporated by reference to Exhibit 10(T) of Form 10-K filed for the year ended December 31, 2003, Commission File Number 0-8135.
     (t)    Summary description of the compensation of Non-Employee Directors of Sigma-Aldrich Corporation. — See Exhibit 10(t).
     (u)    Summary description of the compensation for the Executive Officers of Sigma-Aldrich Corporation — See Exhibit 10(u).
     (v)    Employment Agreement with President and Chief Executive Officer Jai P. Nagarkatti effective January 1, 2006* Incorporated by reference to Exhibit 10.2 of Form 8-K filed January 19 ,2006, Commission File Number 0-8135.
     (w)    Credit Agreement dated February 23, 2005 with Sigma-Aldrich Corporation and a syndicate of banks, including Wells Fargo, National Association and Wachovia Capital Markets, LLC, which served as joint lead arrangers, and other lenders named therein. Incorporated by reference to Exhibit 10.1 of Form 8-K filed February 25, 2005.
11          Statement Regarding Computation of Net Earnings Per Share — Incorporated by reference to the information on net earnings per share included in Note 16 to the Company’s 2005 consolidated financial statements filed as Exhibit 13 below.
13          Pages 17-44 of the Annual Report to Shareholders for the year ended December 31, 2005.
18          Independent Registered Public Accounting Firm’s Preferability Letter concerning the change in the measurement date for the Company’s defined benefit retirement and post retirement welfare benefit plans from December 31 to November 30. Incorporated by reference to Exhibit 18 of Form 10-K filed March 14, 2005, Commission File Number 0-8135.
21          Subsidiaries of Registrant
23          Consent of Independent Registered Public Accounting Firm
31.1       Certification of Chief Executive Officer required by Rule 13a-15(e) and 15d-15(e) under the Exchange Act.
31.2       Certification of Chief Financial Officer required by Rule 13a-15(e) and 15d-15(e) under the Exchange Act.
32.1       CEO Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. See exhibit 32.1.
32.2       CFO Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. See exhibit 32.2.

 

* Represents management contract or compensatory plan or arrangement required to be filed as an exhibit pursuant to Item 15(c) of Form 10-K.

 

F-3

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki